Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-02

Study Completion Date

2024-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This feasibility (small) study aims to see if it is possible to run a large study looking at the effect of lidocaine on large bowel cancer recurrence after surgery in the NHS hospitals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors

NCT05484687

Colorectal Tumors Lidocaine

COMPLETED NA

Local Anesthetic Wound Infusion and Functional Recovery After Colon Surgery

NCT01062919

Colon Cancer Inflammatory Bowel Diseases Diverticulitis

TERMINATED NA

The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery

NCT03462836

Laparoscopic Colorectal Resection Due to Cancer

WITHDRAWN NA

Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery

NCT01346917

Colorectal Cancer

COMPLETED NA

Anesthesia and Postoperative Outcome in Colorectal Cancer Patients

NCT02786329

Colorectal Cancer

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Strong preclinical evidence suggests that lidocaine, a type of local anaesthetic commonly used, could potentially reduce cancer recurrence if given during cancer surgery. This study will evaluate the feasibility of conducting a study comparing intravenous lidocaine infusion versus placebo administration for 24 hours from the start of general anaesthesia. The specific population will be any stage 2 or 3 colon or rectal cancer patient undergoing elective laparoscopic colorectal cancer surgery to look at postoperative cancer outcomes in two NHS settings. This study will explore the acceptability, facilitators and potential barriers of recruiting cancer patients, with possible anxieties of a new cancer diagnosis about to have major surgery along with other potential feasibility issues. It will also assess if follow-up and outcome data collection can be streamlined with usual care processes as much as possible and to guide the future definitive trial.

The project will:

1. Perform a feasibility study. This will be similar in design to the future bigger study and will see:

* if there are any problems in giving lidocaine;
* if patients and clinicians would be happy to take part in a study using a design where some patients get the drug and others get a non-active substance (known as placebo);
* how many patients can we get from the different types and stages of bowel cancer;
* if patients can be followed up successfully;
* if we can collect all the data that we would need;
* what measures might work well for the future study;
2. Look to see if blood tests can give some idea on how lidocaine might work in patients and if it can be confirmed in the bigger study.

The study will involve a small number of patients getting either lidocaine or placebo, and:

* filling in questionnaires to measure quality of life;
* follow up phone call at 6 and 12 months after surgery;
* having their records looked at to see if cancer comes back;
* both patients and clinicians to fill in a feedback questionnaire to see how they get on with the study processes;
* having extra blood tests before and after they finish the lidocaine/placebo infusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Quality of Life Recurrent Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lidocaine

An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.

Group Type ACTIVE_COMPARATOR

Lidocaine hydrochloride 2% for injection

Intervention Type DRUG

An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.

0.9% sterile Sodium Chloride solution for injection

An equivalent infusion rate (ml) of placebo will be administered following the induction of anaesthesia over 20 minutes followed by hourly equivalent intravenous infusion in ml/hr of placebo with a maximum rate of 6mls/hr (equivalent of 120mg/hour for lidocaine) for 24 hours.

Group Type PLACEBO_COMPARATOR

0.9% sterile Sodium Chloride solution for injection

Intervention Type DRUG

Administered as lidocaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine hydrochloride 2% for injection

An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.

Intervention Type DRUG

0.9% sterile Sodium Chloride solution for injection

Administered as lidocaine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xylocaine Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 and above, undergoing laparoscopic surgery with stage 2 or 3 colon cancer
* Age 18 and above, undergoing laparoscopic surgery with stage 2 or 3 rectal cancer
* Ability and willingness to consent

Exclusion Criteria

* Stage 1 and stage 4 colon or rectal cancer
* Palliative surgery with no curative intent
* Extensive comorbidities, i.e. American Society of Anesthesiologists (ASA) Score IV
* Patients with known or suspected allergy to lidocaine
* Patients who are currently pregnant\* or breastfeeding
* Patients who are likely to have adverse effects from the accumulation of intravenous lidocaine:

* current liver disease with a liver function outside the normal laboratory range
* current renal failure (eGFR \<30)
* epilepsy
* cardiac conduction abnormalities based on history and confirmed by electrocardiogram

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No